EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory

Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early vascular recoil and late constrictive remodeling. 

EMINENT Trial | Stent Eluvia vs BMS en territorio femoropoplíteo

Randomized studies have shown that the use of Paclitaxel drug eluting stents (DES) reduces the number of new revascularizations (even though these studies compared mostly against conventional balloons, which is why we have yet to measure impact with the contemporary self-expanding DES) 

The aim of this study (EMINENT) was to compare the ELUVIA (polymer-based paclitaxel eluting stent) vs BMS for the treatment of the superficial femoral artery or proximal popliteal artery in lesions with up to 210 mm total lesion length (tandem lesions allowed). 

It was a multicenter, international study randomizing patients 2:1, including symptomatic patients (Rutherford 2, 3 and 4) with lesion length from 30 to 210 mm. It excluded patients in dialysis, vessels previously treated with stents or surgery and those receiving plaque modifying treatments (atherectomy, laser or debulking). They used stents up to 120 mm (after having discontinued the 150 mm stents). 

Read also: We Should Start Considering Pulmonary Hypertension After TAVR.

Efficacy primary end point was primary patency at one year. Secondary end points included sustained clinical improvement (Rutherford) and adverse effects.

775 patients from 10 European countries were enrolled, 508 received DES stenting and 267 BMS. Most patients were men (70%), mean lesion size was 75.6 mm and 40% were occlusions. 

DES showed greater primary patency at 12 months vs BMS (83.2% vs 74.3%, Difference 8.9%, CI 95% 21.1-15.7%; P<0.01). The absence of adverse effects at 12 months did not differ significantly (88.2% vs 88.2%, P=0.99), both in all-cause mortality (difference 1.6, CI 95% -0.3-3.6; P=0.15) and new revascularization (-1-8%; CI 95% -6.3-2.7%; P=0.43).

Conclusions

The EMINENT is the largest randomized study to date showing the efficacy of DES in femoropopliteal territory. Comparing 775 patients, at 12 months there was a difference in primary patency of 8.9%, without major adverse effects.  

Prior studies on DES such as the BATTLE and the Zilver PTX had not been specifically designed to compare against BMS. This is the main difference with the EMINENT. These data support the use of polymer-based paclitaxel DES in patients with femoropopliteal disease.  

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.

Reference: Gouëffic, Yann et al. “Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.” Circulation, 101161CIRCULATIONAHA122059606. 18 Oct. 2022, doi:10.1161/CIRCULATIONAHA.122.059606.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...